1460774786-9f0646ef-04e3-48fb-9cdf-ae00d5e066db

1. A composite material having a high thermal conductivity and a small thermal expansion coefficient, which is obtained by impregnating a porous graphitized extrudate with a metal; said composite material having such anisotropy that said thermal conductivity and said thermal expansion coefficient are 250 WmK or more and less than 4\xd710\u22126K, respectively, in an extrusion direction; and that said thermal conductivity and said thermal expansion coefficient are 150 WmK or more and 10\xd710\u22126K or less; respectively, in a direction perpendicular to said extrusion direction.
2. (canceled)
3. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 1, wherein said composite material has a bulk density of 1.9 gcm3 or more; and wherein the amount of said metal is 10 to 30% by volume.
4. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 1, wherein the resistivity of said composite material is 4 \u03bc\u03a9m or less in said extrusion direction and 7 \u03bc\u03a9m or less in said perpendicular direction.
5. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 1, wherein said metal is at least one metal selected from the group consisting of aluminum, copper, chromium, silver, magnesium and zinc, or an alloy comprising one or more of said metals.
6. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 5, wherein said metal is an aluminum alloy comprising 11 to 14% by mass of silicon, the balance being substantially aluminum and inevitable impurities, and wherein the percentage of a needle-shaped structure having a length of 30 \u03bcm or less and an aspect ratio (lengthdiameter) of 10 or more is 10% or less among a silicon (Si)-rich phase precipitated in said metal.
7. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 5, wherein said metal is copper or a copper alloy; and wherein the amount of oxygen in said metal is 400 ppm or less.
8-17. (canceled)
18. A heat-dissipating substrate comprising the composite material having a high thermal conductivity and a small thermal expansion coefficient recited in claim 1, wherein the thickness direction of said substrate is substantially in alignment with the extrusion direction of said porous graphitized extrudate; and wherein said substrate has a surface perpendicular to said extrusion direction, onto which a heat-generating body is going to be bonded.
19. The heat-dissipating substrate according to claim 18, wherein a metal layer having such sealability that the amount of a helium gas leaked is 1\xd710\u22122 Pa\xb7cm3s or less is formed on at least on a surface, onto which a heat-generating body is going to be bonded.
20. The heat-dissipating substrate according to claim 19, wherein said metal layer comprises a Ni\u2014B plating layer andor a Ni\u2014P plating layer each having a thickness of 0.5 to 20 \u03bcm.
21. The heat-dissipating substrate according to claim 18, wherein said substrate has throughholes, in each of which a reinforcing pipe member is fitted.
22-24. (canceled)
25. The composite material having a high thermal conductivity and a small thermal expansion coefficient according to claim 1, wherein a ratio of the thermal expansion coefficient in the perpendicular direction to that in the extrusion direction is 2 or more.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (1)
R\u2014NH\u2014CH(R1)\u2014CH2\u2014S\u2014S\u2014C(R2)(R3)\u2014COCH2\u2014CH(R4)\u2014COR5\u2003\u2003(1)
wherein R is:
a) R is:
hydrogen;
an alkoxyalkylcarbonyl group R\u2032C(O)OCH(R\u2033)OC(O)\u2014 where R\u2032 and R\u2033 are, independently, an alkyl group containing 1 to 6 carbon atoms;

b) R1 is a linear or branched alkyl group of 1 to 6 carbon atoms, substituted, or not, by an \u2014OR\u2032\u2033, \u2014SOR\u2032\u2033 or \u2014SR\u2032\u2033 group, with R\u2032\u2033 being an alkyl group of 1 to 6 carbon atoms, substituted, or not, by one or more halogen atoms;
c) R2 is:
a linear or branched alkyl group of 1 to 6 carbon atoms, substituted or not, by:
an \u2014OR6, \u2014SR6 or \u2014SOR6 group, with R6 being hydrogen, a linear or branched alkyl group of 1 to 4 carbons, a phenyl or benzyl group;
a \u2014CO2R7 group, with R7 being hydrogen, a linear or branched alkyl group comprising 2 to 4 carbon atoms, or a benzyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a saturated 5- or 6-membered heterocycle comprising one or more heteroatoms selected from N or O; or
a carboxamide group \u2014CONR8R9, with \u2014NR8R9 as defined above;
a phenyl group, substituted, or not, by one or more halogens selected from fluorine or bromine, an alkoxy group \u2014OR6, with R6 having the same definition as above, or by a phenyl group;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;

a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur; or
a phenyl group, substituted or not, by one or more halogens selected from fluorine or bromine, or by an \u2014OR5 group with R5 having the same definition as above;
and R3 is hydrogen; or
R2 and R3 are identical and are a linear or branched alkyl group of 1 to 6 carbon atoms; or
\u2014C(R2)(R3)\u2014 taken together is:
a saturated 5-membered cyclic compound fused, or not, to an aromatic ring;
a saturated 6-membered cyclic compound;
a saturated 6-membered heterocyclic compound comprising 1 heteroatom, at the 4-position, selected from oxygen, nitrogen and sulfur, wherein when the heteroatom is nitrogen, the nitrogen is substituted, or not, by an alkyl group of 1 to 6 carbon atoms, a phenyl, benzyl or alkanoyl group;
d) R4 is:
a linear or branched alkyl group of 1 to 6 carbon atoms, substituted, or not, by:
an \u2014OR6, \u2014SR6 or \u2014SOR6 group, with R6 being hydrogen, a linear or branched alkyl group of 1 to 4 carbons, a phenyl or benzyl group;
a \u2014CO2R7 group, with R7 being hydrogen, a linear or branched alkyl group comprising 2 to 4 carbon atoms, a benzyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a saturated 5- or 6-membered heterocycle comprising one or more heteroatoms selected from N or O;
a carboxamide group \u2014CONR8R9, with \u2014NR8R9 as defined above;
a phenyl group substituted, or not, by:
one or more halogens selected from fluorine or bromine;
an \u2014OR6 group, R6 having the same definition as above;
a phenyl or thienyl group;

an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur; or
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;

a phenyl group, substituted or not, by:
one or more halogens;
an \u2014OR6 group, with R6 having the same definition as above;
a phenyl;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
e) R5 is:
a hydroxyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a 5- or 6-membered heterocycle, comprising one or more heteroatoms selected from N or O;
an alkoxy group \u2014OR10, with R10 being:
a linear or branched alkyl group, comprised of 2 to 6 carbon atoms;
a benzyl group;
a \u2014CHR11\u2014COOR12, \u2014CHR11\u2014O\u2014C(\u2550O)R12, \u2014CHR11\u2014C(\u2550O)\u2014OR12 group wherein R11 and R12 are, independently, a linear or branched alkyl group of 1 to 6 carbon atoms.
2. The compound according to claim 1, wherein R2 is a linear or branched alkyl group of 1 to 6 carbon atoms or a linear or branched alkyl group of 1 to 6 carbon atoms substituted by:
a phenyl group;
a phenyl group substituted by one or more halogens selected from fluorine or bromine;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
and R3 is hydrogen, or
R2 and R3 are identical and are a linear or branched alkyl group of 1 to 6 carbon atoms, or
\u2014C(R2)(R3)\u2014 taken together is:
a saturated 5-membered cyclic compound;
a saturated 5-membered cyclic compound fused to an aromatic ring;
a saturated 6-membered cyclic compound; or
a saturated 6-membered heterocyclic compound comprising 1 heteroatom, at the 4-position, selected from oxygen, nitrogen and sulfur.
3. The compound according to claim 1, wherein R4 is a linear or branched alkyl group of 1 to 6 carbon atoms substituted by:
a phenyl group; or
a phenyl group substituted by:
one or more halogens selected from fluorine or bromine;
a phenyl or thienyl group.
4. The compound according to claim 1, wherein R5 is a hydroxyl.
5. The compound according to claim 1, wherein:
a) R1 is selected from \u2014CH2CH2SCH3, \u2014CH2CH2SOCH3, \u2014CH2CH2CH2CH3;
b) R2 is a linear or branched alkyl group of 1 to 6 carbon atoms or a linear or branched alkyl group of 1 to 6 carbon atoms substituted by:
a phenyl group;
a phenyl group substituted by one or more halogens selected from fluorine or bromine;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
and R3 is hydrogen, or
R2 and R3 are identical and are a linear or branched alkyl group of 1 to 6 carbon atoms; or
\u2014C(R2)(R3)\u2014 taken together is:
a saturated 5-membered cyclic compound;
a saturated 5-membered cyclic compound fused to an aromatic ring;
a saturated 6-membered cyclic compound; or
a saturated 6-membered heterocyclic compound comprising 1 heteroatom, at the 4-position, selected from oxygen, nitrogen and sulfur;
c) R4 is a linear or branched alkyl group of 1 to 6 carbon atoms substituted by:
a phenyl group; or
a phenyl group substituted by:
one or more halogens selected from fluorine or bromine;
a phenyl or thienyl group;
d) R5 is a hydroxyl group.
6. The compound according to claim 1, wherein R2 is an isobutyl group or a methyl group substituted by:
a phenyl group;
a phenyl group substituted at the 4-position by a halogen selected from fluorine or bromine;
a phenyl group substituted at the 4-position by a phenyl group;
and R3 is hydrogen, or
R2 and R3 are identical and are a methyl or ethyl group, or
\u2014C(R2)(R3)\u2014 are together:
a saturated 5- or 6-membered cyclic group; or
a saturated 5-membered cyclic group fused to an aromatic ring.
7. The compound according to claim 1, wherein R4 is an alkyl group with one carbon substituted by:
a phenyl group;
a phenyl group substituted at the 4-position by a halogen selected from fluorine or bromine;
a phenyl group substituted at the 4-position by a phenyl group.
8. The compound according to claim 1, wherein:
\u2014R2=CH2Ph; R3=H; R4=CH2Ph; or
\u2014R2=iBu; R3=H; R4=CH2(4-Br-Ph); or
\u2014R2=CH2(4-Br-Ph); R3=H; R4=CH2(4-Br-Ph); or
\u2014R2=CH2(4-Br-Ph); R3=H; R4=CH2Ph;
\u2014R2=CH2Ph; R3=H; R4=CH2(4-Br-Ph); or
\u2014R2=CH2(4-Ph-Ph); R3=H; R4=CH2(4-Br-Ph); or
\u2014R2=CH3; R3=CH3; R4=CH2(4-Br-Ph); or
\u2014R2=C2H5; R3=C2H5; R4=CH2(4-Br-Ph); or
\u2014C(R2)(R3)=C5H8; R4=CH2(4-Br-Ph); or
\u2014C(R2)(R3)=C6H10; R4=CH2(4-Br-Ph); or
\u2014C(R2)(R3)=C9H8; R4=CH2(4-Br-Ph); or
\u2014C(R2)(R3)=C6H10; R4=CH2(4-Ph-Ph); or
\u2014C(R2)(R3)=C5H8; R4=CH2(4-Br-Ph); or
\u2014C(R2)(R3)=C9H8; R4=CH2(4-Ph-Ph).
9. The compound according to claim 1, wherein R1 is selected from \u2014CH2CH2SCH3, CH2CH2SOCH3, \u2014CH2CH2CH2CH3.
10. The compound according to claim 1 wherein:
\u2014R1=CH2CH2SCH3; R2=CH2CH(CH3)2; R3=H; R4=CH2(4-Br-Ph);
\u2014R1=CH2CH2CH2CH3; R2=CH2CH(CH3)2; R3=H; R4=CH2(4-Br-Ph);
\u2014R1=CH2CH2SOCH3; R2=CH2CH(CH3)2; R3=H; R4=CH2(4-Br-Ph);
\u2014R1=CH2CH2CH2CH3; C(R2)(R3)\u2014=Cyclohexyl; R4=CH2(4-Br-Ph);
\u2014R1=CH2CH2SCH3; C(R2)(R3)=Cyclohexyl; R4=CH2(4-Ph-Ph);
\u2014R1=CH2CH2CH2CH3; C(R2)(R3)=Cyclohexyl; R4=CH2(4-Ph-Ph).
11. The compound according to claim 1, formulated as a drug.
12. The compound according to claim 11, formulated as an analgesic, anxiolytic, antidepressant or anti-inflammatory.
13. A pharmaceutical composition comprising at least one compound of formula (1)
R\u2014NH\u2014CH(R1)\u2014CH2\u2014S\u2014S\u2014C(R2)(R3)\u2014COCH2\u2014CH(R4)\u2014COR5\u2003\u2003(1)
wherein R is:
a) R is:
hydrogen;
an alkoxyalkylcarbonyl group R\u2032C(O)OCH(R\u2033)OC(O)\u2014 where R\u2032 and R\u2033 are, independently, an alkyl group containing 1 to 6 carbon atoms;

b) R1 is a linear or branched alkyl group of 1 to 6 carbon atoms, substituted, or not, by an \u2014OR\u2032\u2033, \u2014SOR\u2032\u2033 or \u2014SR\u2032\u2033 group, with R\u2032\u2033 being an alkyl group of 1 to 6 carbon atoms, substituted, or not, by one or more halogen atoms;
c) R2 is:
a linear or branched alkyl group of 1 to 6 carbon atoms, substituted or not, by:
an \u2014OR6, \u2014SR6 or \u2014SOR6 group, with R6 being hydrogen, a linear or branched alkyl group of 1 to 4 carbons, a phenyl or benzyl group;
a \u2014CO2R7 group, with R7 being hydrogen, a linear or branched alkyl group comprising 2 to 4 carbon atoms, or a benzyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a saturated 5- or 6-membered heterocycle comprising one or more heteroatoms selected from N or O; or
a carboxamide group \u2014CONR8R9, with \u2014NR8R9 as defined above;
a phenyl group, substituted, or not, by one or more halogens selected from fluorine or bromine, an alkoxy group \u2014OR6, with R6 having the same definition as above, or by a phenyl group;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;

a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur; or
a phenyl group, substituted or not, by one or more halogens selected from fluorine or bromine, or by an \u2014OR5 group with R5 having the same definition as above;
and R3 is hydrogen; or
R2 and R3 are identical and are a linear or branched alkyl group of 1 to 6 carbon atoms; or
\u2014C(R2)(R3)\u2014 taken together is:
a saturated 5-membered cyclic compound fused, or not, to an aromatic ring;
a saturated 6-membered cyclic compound;
a saturated 6-membered heterocyclic compound comprising 1 heteroatom, at the 4-position, selected from oxygen, nitrogen and sulfur, wherein when the heteroatom is nitrogen, the nitrogen is substituted, or not, by an alkyl group of 1 to 6 carbon atoms, a phenyl, benzyl or alkanoyl group;
d) R4 is:
a linear or branched alkyl group of 1 to 6 carbon atoms, substituted, or not, by:
an \u2014OR6, \u2014SR6 or \u2014SOR6 group, with R6 being hydrogen, a linear or branched alkyl group of 1 to 4 carbons, a phenyl or benzyl group;
a \u2014CO2R7 group, with R7 being hydrogen, a linear or branched alkyl group comprising 2 to 4 carbon atoms, a benzyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a saturated 5- or 6-membered heterocycle comprising one or more heteroatoms selected from N or O;
a carboxamide group \u2014CONR8R9, with \u2014NR8R9 as defined above;
a phenyl group substituted, or not, by:
one or more halogens selected from fluorine or bromine;
an \u2014OR6 group, R6 having the same definition as above;
a phenyl or thienyl group;

an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur; or
a saturated 5- or 6-membered cyclic or heterocyclic compound comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;

a phenyl group, substituted or not, by:
one or more halogens;
an \u2014OR6 group, with R6 having the same definition as above;
a phenyl;
an aromatic 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur;
e) R5 is:
a hydroxyl group;
an \u2014NR8R9 group, with R8 and R9 being, independently, hydrogen, a linear or branched alkyl group of 1 to 4 carbon atoms, a phenyl or benzyl group, or with \u2014NR8R9 taken together being a 5- or 6-membered heterocycle, comprising one or more heteroatoms selected from N or O;
an alkoxy group \u2014OR10, with R10 being:
a linear or branched alkyl group, comprised of 2 to 6 carbon atoms;
a benzyl group;
a \u2014CHR11\u2014COOR12, \u2014CHR11\u2014O\u2014C(\u2550O)R12, \u2014CHR11\u2014C(\u2550O)\u2014OR12 group wherein R11 and R12 are, independently, a linear or branched alkyl group of 1 to 6 carbon atoms; and
at least one pharmaceutically acceptable excipient.
14. The pharmaceutical composition according to claim 13, which is an analgesic, anxiolytic, antidepressant or anti-inflammatory.
15. The pharmaceutical composition according to claim 13, comprising at least one compound selected from the group consisting of morphine, endocannabinoids, and inhibitors of endocannabinoid metabolism, gabapentin, pregabalin, duloxetine and methadone.
16. The pharmaceutical composition according to claim 13, adapted for parenteral, topical, oral, or nasal administration.
17. A method for treating pain, depression, anxiety or inflammation, said method comprising administering, to a patient in need thereof, an effective dose of a compound of formula (1) according to claim 1, or a pharmaceutically acceptable salt thereof.
18. The method of claim 17, further comprising administering an effective amount of at least one compound selected from the group consisting of morphine, endocannabinoids, inhibitors of endocannabinoid metabolism, gabapentin, pregabalin, duloxetine and methadone.
19. The method of claim 17, wherein the compound of formula (1) is administered via parenteral, topical, oral, or nasal route.
20. A method for treating pain, depression, anxiety or inflammation, said method comprising administering, to a patient in need thereof, an effective dose of a composition according to claim 13.